NCT05601440 2026-02-11Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerCanadian Cancer Trials GroupPhase 2 Recruiting484 enrolled